Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMRIX vs ALBENDAZOLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.
Albendazole inhibits tubulin polymerization by binding to beta-tubulin, disrupting microtubule formation, which leads to impaired glucose uptake and depletion of glycogen stores in susceptible parasites, resulting in their immobilization and death.
Treatment of spasticity due to multiple sclerosis, spinal cord injury, or other spinal cord disorders
Cystic hydatid disease (Echinococcus granulosus),Neurocysticercosis (Taenia solium),Giardiasis (off-label),Cutaneous larva migrans (off-label),Trichuriasis (off-label),Ascariasis (off-label),Hookworm infections (off-label)
15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.
400 mg orally twice daily for 3-7 days for most indications; for neurocysticercosis, 400 mg orally twice daily for 8-30 days; for hydatid disease, 400 mg orally twice daily for 28-day cycles with 14-day drug-free intervals for 3 cycles.
Terminal elimination half-life approximately 32 hours (range 28–40 hours); clinically relevant for once-daily dosing in chronic muscle spasm
Terminal half-life of albendazole sulfoxide is 8–12 hours; parent drug half-life is <1 hour. Clinical context: supports once- or twice-daily dosing.
Hepatic via deamination; primarily metabolized by monoamine oxidase B (MAO-B) to inactive metabolites.
Primarily hepatic via microsomal enzymes; undergoes oxidation to albendazole sulfoxide (active metabolite) by CYP3A4 and flavin-containing monooxygenases (FMO). Further metabolized to albendazole sulfone (inactive) and other oxidative metabolites.
Renal: approximately 40% as unchanged drug and metabolites; biliary/fecal: minimal; total clearance: 2.5 L/min
Primarily renal (80%) as inactive metabolites; <2% unchanged in urine. Biliary/fecal excretion accounts for ~20%.
40–45% bound to serum proteins, primarily albumin
70% bound to plasma proteins, primarily albumin.
5–8 L/kg; suggests extensive tissue distribution, including skeletal muscle
0.2–0.6 L/kg, indicating distribution into tissues; concentrates in liver, bile, and cerebrospinal fluid.
Oral: 85–95% (extended-release formulation)
Oral bioavailability is low (~5%) due to extensive first-pass metabolism; co-administration with a high-fat meal increases bioavailability up to 4–5-fold.
No specific dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min).
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <15 m L/min), use with caution; consider dose reduction or extended intervals. No specific GFR-based guidelines available.
Contraindicated in Child-Pugh class C. For Child-Pugh class A or B: initiate at 15 mg once daily; do not increase dose. Use with caution.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution; monitor liver function. No specific dose adjustment guidelines available.
Safety and efficacy not established in pediatric patients under 12 years. For ages 12 and older, same as adult dosing.
For children >2 years: 15 mg/kg/day orally in 2 divided doses (max 800 mg/day) for most indications. For neurocysticercosis: 15 mg/kg/day orally in 2 divided doses (max 800 mg/day) for 8-30 days. For hydatid disease: 15 mg/kg/day orally in 2 divided doses (max 800 mg/day) for 28-day cycles with 14-day drug-free intervals. For children <2 years: safety and efficacy not established.
Initiate at 15 mg once daily. Due to higher incidence of anticholinergic effects and falls, monitor closely; consider lower doses in frail elderly.
No specific dose adjustment recommended; use with caution due to potential age-related hepatic or renal impairment. Monitor liver function and blood counts regularly.
None
Albendazole may cause fetal harm when administered to pregnant women. It is contraindicated in pregnancy and should not be used in women who are or may become pregnant. Women of childbearing potential should have a negative pregnancy test before starting treatment and should use effective contraception during therapy and for one month after completion.
Abrupt discontinuation may precipitate withdrawal syndrome including hallucinations, seizures, autonomic instability.,May cause sedation, dizziness, and muscle weakness; caution with activities requiring alertness.,Use with caution in patients with impaired renal function due to reduced clearance.,May exacerbate seizures in patients with epilepsy.,Avoid concomitant use with other CNS depressants.
Bone marrow suppression: Monitor CBC at start and periodically; risk of pancytopenia, particularly in patients with hepatic disease or receiving high doses.,Hepatotoxicity: Monitor liver function tests due to risk of elevated transaminases and rare hepatic failure.,Risk of neurocysticercosis exacerbation: May cause increased intracranial pressure or seizures; treat with corticosteroids and anticonvulsants as needed.,Retinal damage: In ocular neurocysticercosis, evaluate for retinal lesions before therapy due to risk of retinal damage from inflammation.,Renal impairment: Use with caution; dose adjustment may be necessary.,Lactation: Excreted in breast milk; caution in nursing mothers.
Hypersensitivity to amrix or baclofen.,Abrupt withdrawal is contraindicated; must be tapered.,Concomitant use with MAO inhibitors is contraindicated due to risk of hypertensive crisis.
Pregnancy (absolute),Known hypersensitivity to albendazole or any of its components,Patients with pre-existing bone marrow suppression (relative)
Avoid grapefruit and grapefruit juice during treatment as they may increase cyclobenzaprine levels. Taking AMRIX with or without food does not significantly affect absorption. Alcohol should be strictly avoided as it potentiates CNS depression.
Take with a high-fat meal (≥40 g fat) to significantly increase oral bioavailability. Avoid grapefruit juice as it may affect drug metabolism. No specific dietary restrictions otherwise.
Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacking. Use only if clearly needed. First trimester: no specific teratogenic effects documented; second and third trimesters: avoid near term due to potential neonatal effects (e.g., sedation, withdrawal).
FDA Category C. First trimester: risk of skeletal abnormalities and embryotoxicity based on animal studies. Second and third trimesters: limited human data, but potential for fetal harm; avoid use unless benefit outweighs risk.
Cyclobenzaprine is excreted into human milk in small amounts. M/P ratio: not established. Use with caution in nursing mothers; monitor infant for sedation, poor feeding, or hypotonia.
Excreted in breast milk; M/P ratio not established. Use with caution, especially in neonates due to risk of bone marrow suppression.
No specific dose adjustments are recommended based on pharmacokinetic changes in pregnancy; however, due to potential for increased clearance, lowest effective dose should be used. Avoid use during labor and delivery due to potential neonatal depression.
No specific dose adjustment recommended in pregnancy; pharmacokinetic changes not well studied. Use lowest effective dose and shortest duration possible.
AMRIX (cyclobenzaprine extended-release) should not be used longer than 2-3 weeks due to lack of evidence for efficacy in muscle spasm beyond that period. It has significant anticholinergic effects; avoid in patients with glaucoma, urinary retention, or those taking MAOIs. Do not crush or chew capsules; administer once daily at same time. Onset of action is delayed compared to immediate-release cyclobenzaprine.
Albendazole is a broad-spectrum anthelmintic that inhibits microtubule polymerization by binding to beta-tubulin. It is highly effective against Echinococcus granulosus cysts but requires prolonged therapy (e.g., 28-day cycles). Monitor liver function tests (LFTs) at baseline and every 2 weeks due to risk of hepatotoxicity. For neurocysticercosis, co-administer corticosteroids to reduce inflammatory reaction from cyst degeneration. Albendazole is pregnancy category C; avoid in first trimester and in women planning pregnancy within 1 month of therapy. Absorption is enhanced by a fatty meal; administer with a high-fat meal to increase bioavailability up to 5-fold.
Take AMRIX exactly once daily at the same time each day; do not crush, chew, or open the capsule.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase the risk of severe drowsiness and dizziness.,Do not drive or operate heavy machinery until you know how AMRIX affects you; it may cause drowsiness, dizziness, or blurred vision.,Contact your healthcare provider if you experience symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness, nausea, diarrhea).,Do not use AMRIX for longer than 2-3 weeks unless specifically directed by your doctor; prolonged use is not recommended.,Inform your doctor if you have a history of urinary retention, glaucoma, thyroid disorders, heart problems, or liver disease.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double the dose.
Take this medication with a fatty meal (e.g., eggs, avocado, nuts) to improve absorption.,Do not crush or chew the tablets; swallow them whole with water.,Complete the full course of therapy even if you feel better.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe nausea, or abdominal pain.,Avoid pregnancy during treatment and for at least 1 month after the last dose; use reliable contraception.,You may experience dizziness or blurred vision; avoid driving or operating machinery until you know how the drug affects you.,If you are breastfeeding, discuss with your doctor before taking this medication.
No interactions on record
"Albendazole inhibits the CYP3A4-mediated metabolism of clemastine, leading to increased plasma concentrations of clemastine. This can potentiate the anticholinergic and sedative effects of clemastine, including dry mouth, urinary retention, constipation, and drowsiness. Patients may experience heightened central nervous system depression, especially with concurrent use of other CNS depressants."
"Ranolazine, a piperazine derivative antianginal agent, is a moderate CYP3A4 inhibitor. Albendazole is primarily metabolized by CYP3A4 to its active metabolite, albendazole sulfoxide. Coadministration increases albendazole systemic exposure by approximately 50%, potentially enhancing both therapeutic efficacy and dose-dependent toxicities, including hepatotoxicity and bone marrow suppression."
"Albendazole inhibits CYP3A4, the enzyme primarily responsible for the metabolism of lovastatin. This inhibition reduces lovastatin clearance, leading to elevated plasma concentrations and increased risk of statin-related adverse effects such as myopathy, rhabdomyolysis, and hepatotoxicity. Patients receiving this combination should be monitored closely for signs of muscle pain or weakness and liver enzyme abnormalities."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMRIX vs ALBENDAZOLE, answered by our medical review team.
AMRIX is a Muscle Relaxant that works by Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.. ALBENDAZOLE is a Anthelmintic that works by Albendazole inhibits tubulin polymerization by binding to beta-tubulin, disrupting microtubule formation, which leads to impaired glucose uptake and depletion of glycogen stores in susceptible parasites, resulting in their immobilization and death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMRIX and ALBENDAZOLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMRIX is: 15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.. The standard adult dose of ALBENDAZOLE is: 400 mg orally twice daily for 3-7 days for most indications; for neurocysticercosis, 400 mg orally twice daily for 8-30 days; for hydatid disease, 400 mg orally twice daily for 28-day cycles with 14-day drug-free intervals for 3 cycles.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMRIX and ALBENDAZOLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMRIX is classified as Category C. Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacki. ALBENDAZOLE is classified as Category D/X. FDA Category C. First trimester: risk of skeletal abnormalities and embryotoxicity based on animal studies. Second and third trimesters: limited human data, but potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.